Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pharmaron Beijing Co., Ltd. (300759.SZ)
Beijing, BJ, CN
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.32% | -2.41% | -14.36% | -15.20% | -13.30% | -11.71% | +5.29% | -18.32% | -68.68% | +412.24% | +412.24% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 8 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+14.8% ★ Q1'26: +15.5% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%-6.9% Q1'26: +11.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+10.4% ★ Q1'26: +1.0% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+14.5% ★ Q1'26: +12.9% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+9.5% ★ Q1'26: +6.5% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%-0.1% ★ Q1'26: +2.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×1.12× Q1'26: 2.49× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 5 EPS Ana. |
Dec 2027 12 Rev. Ana. 8 EPS Ana. |
Dec 2028 9 Rev. Ana. 8 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.91B
est: 2.94B (-1.1%)
|
3.76B
est: 3.77B (-0.3%)
|
5.13B
est: 5.13B (+0.1%)
|
7.44B
est: 7.38B (+0.9%)
|
10.27B
est: 10.24B (+0.2%)
|
11.54B
est: 11.50B (+0.3%)
|
12.28B
est: 12.24B (+0.3%)
|
14.10B
est: 14.03B (+0.4%)
|
16.29B
16.13B – 16.40B
+16.1% YoY
|
18.79B
18.29B – 19.39B
+15.4% YoY
|
21.81B
21.75B – 21.87B
+16.1% YoY
|
| EBITDA |
640.95M
est: 672.98M (-4.8%)
|
928.02M
est: 863.14M (+7.5%)
|
1.32B
est: 1.17B (+12.8%)
|
1.85B
est: 1.69B (+9.6%)
|
2.23B
est: 2.35B (-5.0%)
|
2.43B
est: 2.54B (-4.2%)
|
2.58B
est: 2.70B (-4.4%)
|
3.05B
est: 3.10B (-1.4%)
|
3.59B
3.56B – 3.62B
+16.1% YoY
|
4.15B
4.04B – 4.28B
+15.4% YoY
|
4.81B
4.80B – 4.83B
+16.1% YoY
|
| EBIT |
430.81M
est: 494.92M (-13.0%)
|
665.16M
est: 634.77M (+4.8%)
|
1.02B
est: 863.48M (+18.1%)
|
1.45B
est: 1.24B (+16.5%)
|
1.67B
est: 1.72B (-3.4%)
|
1.69B
est: 1.81B (-6.8%)
|
1.72B
est: 1.93B (-10.9%)
|
2.05B
est: 2.21B (-7.6%)
|
2.57B
2.54B – 2.59B
+16.1% YoY
|
2.96B
2.88B – 3.06B
+15.4% YoY
|
3.44B
3.43B – 3.45B
+16.1% YoY
|
| Net Income |
333.04M
est: 441.37M (-24.5%)
|
547.19M
est: 545.80M (+0.3%)
|
1.17B
est: 1.09B (+7.6%)
|
1.66B
est: 1.57B (+5.7%)
|
1.37B
est: 1.58B (-13.3%)
|
1.60B
est: 1.93B (-17.0%)
|
1.79B
est: 1.82B (-1.6%)
|
1.66B
est: 1.69B (-1.8%)
|
1.97B
1.96B – 1.98B
+16.4% YoY
|
2.49B
2.18B – 2.58B
+26.4% YoY
|
3.14B
2.55B – 4.14B
+26.0% YoY
|
| SGA |
449.23M
est: 448.06M (+0.3%)
|
568.58M
est: 574.67M (-1.1%)
|
745.89M
est: 781.72M (-4.6%)
|
1.02B
est: 1.13B (-9.1%)
|
1.73B
est: 1.56B (+10.7%)
|
1.86B
est: 1.75B (+6.1%)
|
1.84B
est: 1.86B (-1.1%)
|
2.04B
est: 2.14B (-4.5%)
|
2.48B
2.46B – 2.50B
+16.1% YoY
|
2.86B
2.79B – 2.95B
+15.4% YoY
|
3.32B
3.31B – 3.33B
+16.1% YoY
|
| EPS |
0.38
est: 0.25 (+52.7%)
|
0.83
est: 0.31 (+169.7%)
|
1.48
est: 0.61 (+140.8%)
|
2.10
est: 0.89 (+137.0%)
|
0.78
est: 0.89 (-12.7%)
|
0.90
est: 1.09 (-17.2%)
|
1.01
est: 1.03 (-1.7%)
|
0.94
est: 0.94 (-0.1%)
|
1.11
1.11 – 1.12
+18.3% YoY
|
1.38
1.23 – 1.46
+23.8% YoY
|
1.70
1.44 – 2.34
+23.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-11 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-08 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-07 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-06 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-30 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-23 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X China Biotech ETF (HKD) 2820.HK | 2.76% | 2.21M | 0.68% |
| 2 | KraneShares MSCI All China Health Care Index ETF KURE | 1.25% | 991.9K | 0.79% |
| 3 | VanEck ChiNext ETF CNXT | 0.50% | 603.8K | 0.65% |
| 4 | JPMorgan ETFs (Ireland) ICAV - China A Research Enhanced Index Equity Active UCITS ETF JREC.L | 0.49% | 111.5K | 0.40% |
| 5 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.33% | 122.6K | 0.65% |
| 6 | Amundi MSCI EM Asia SRI Climate Paris Aligned UCITS ETF DR (D) SADA.L | 0.23% | 480.5K | 0.25% |
| 7 | Amundi MSCI Emerging Markets SRI Climate Paris Aligned UCITS ETF DR (C) MSRU.L | 0.13% | 3.76M | 0.25% |
| 8 | Amundi MSCI Emerging Markets SRI Climate Paris Aligned UCITS ETF DR (D) MSDU.L | 0.13% | 3.76M | 0.25% |
| 9 | iShares MSCI China A UCITS ETF CNYA.L | 0.10% | 2.93M | 0.40% |
| 10 | iShares MSCI China A UCITS ETF CNYE.MI | 0.10% | 96.6K | 0.45% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Boliang Lou | Chairman & Chief Executive Officer | 2M | — |
| Xiaoqiang Lou | Co-Founder, President, Chief Operating Officer & Executive Director | 2M | male |
| Bei Zheng | Executive Vice President & Executive Director | 2M | female |
| Connie Sun | Senior Vice President & Global Head of Business Development of Small Molecules | — | — |
| Hua Yang | Chief Scientific Officer & Deputy Manager | — | — |
| Jingqi Huang | Senior Vice President of In Vivo Pharmacology | — | — |
| Katherine Lee | Chief Business Officer | — | female |
| Mandy Xu | Senior Vice President of DMPK | — | — |
| Shing Chung Li | CFO, Secretary of the Board, Accounting Supervisor & Employee Representative Director | — | male |
| Sid Bhoopathy | Senior Vice President and US Head of Laboratory Services & CGT | — | — |
| Stephen Lewinton | Senior Vice President of UK Operations | — | male |
| Celina Zhong | Senior Vice President of Human Resources | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300759.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
